2015
DOI: 10.1371/journal.pone.0125364
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: BackgroundDifferent strategies for neoadjuvant chemotherapy in patients with early stage NSCLC have already been evaluated. The aim of this study was to evaluate the tolerability and efficacy of a chemoimmunotherapy when limited to two cycles.MethodsBetween 01/2007 and 03/2010 41 patients with primarily resectable NSCLC stage IB to IIIA were included. Treatment consisted of two cycles cisplatin (40 mg/m2 d1+2) and docetaxel (75 mg/m2 d1) q3 weeks, accompanied by the administration of cetuximab (400 mg/m2 d1, t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2017
2017
2017
2017

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 19 publications
(31 reference statements)
0
3
0
Order By: Relevance
“…Previous studies showed an increase in survival rates in clinical trials using this treatment combined with chemotherapy 51-54 . Presently, there are promising studies using cetuximab in combination with other drugs, such as cisplatin and docetaxel, as neoadjuvant treatment of early-stage NSCLC 55 . Although it is a rare, severe allergic reactions during the first infusion can lead to respiratory reactions and elevated blood pressure.…”
Section: Target Therapies With Biological Moleculesmentioning
confidence: 99%
See 2 more Smart Citations
“…Previous studies showed an increase in survival rates in clinical trials using this treatment combined with chemotherapy 51-54 . Presently, there are promising studies using cetuximab in combination with other drugs, such as cisplatin and docetaxel, as neoadjuvant treatment of early-stage NSCLC 55 . Although it is a rare, severe allergic reactions during the first infusion can lead to respiratory reactions and elevated blood pressure.…”
Section: Target Therapies With Biological Moleculesmentioning
confidence: 99%
“… Related Molecule Target Mechanism of action Potentials adverse effects Reference Cetuximab EGF receptor Inhibition of cell proliferation, enhanced apoptosis, and reduced angiogenesis, invasiveness and metastasis. Rash on face and chest, diarrhea, loss of appetite and fatigue 54-59 Bevacizumab VEGF Selectively binds to VEGF and prevents interaction with its receptor. Anti-angiogenic agent, which prevents the abnormal growth of blood vessels around tumor.…”
Section: Target Therapies With Biological Moleculesmentioning
confidence: 99%
See 1 more Smart Citation